Novo Nordisk A/S’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition ...

Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...